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Abstract
Background: Menstrual blood contains mesenchymal stem cells (MenSC), considered a potential ‘‘off-the-
shelf’’ treatment for a range of diseases and medical conditions. Samples of menstrual blood can be collected
painlessly, inexpensively, and as frequently as every month for cell therapy. While there has been considerable
previous research into the clinical advantages of MenSC, there is currently little understanding of potential
donors’ attitudes regarding menstrual blood donation and MenSC.
Methods: One hundred women 18 years of age or over were surveyed to understand attitudes and potential
barriers to menstrual blood donation. The questionnaire assessed participant age and brief medical history
(giving birth, donating blood, donating stem cells), menstrual experience (period rating, preferred menstrual
hygiene products), and whether participants would donate MenSC or accept MenSC therapy.
Results: MenSC was met with a generally positive response, with 78% of menstruating women willing to
donate menstrual blood. No significant relationship was recognized between willingness to donate menstrual
blood with age, history of childbirth or blood donation, menstruation perception, and preferred menstrual
hygiene product. Women rated their period experience better after being made aware of the ability to donate
menstrual blood, meaning MenSC therapy can be beneficial for donors as well as patients.
Conclusions: Considering women’s attitudes to MenSC and donation of menstrual blood, the future of MenSC
therapy is positive; women are generally willing to donate menstrual blood, independent of age, perception of
periods, and history of childbirth and blood donation.
Keywords: menstrual blood-derived mesenchymal stem cells, donation, human factors, menstrual blood, stem
cells, menstruation
Introduction
Stem cells are cells with the ability for long-term self-renewal and differentiation into multiple specialized
cells.1 Embryonic stem cells are pluripotent stem cells (dif-
ferentiating into all adult cell types) that would therefore
appear to have huge potential for treating a huge number of
diseases and conditions. However, embryonic stem cells that
come with the ethical dilemma of requiring the destruction of
an embryo, are not widely available, and are susceptible to
teratoma formation, which is a major health risk for the
embryonic stem cell transplant recipients.2–4 Adult stem cells
are found across the body, and are ethically donated with
consent from bone marrow, fat tissue, dental pulp, and pe-
ripheral blood. However, harvesting these cells require painful,
invasive procedures, needing specialist staff and equipment,
all at a high cost. Postnatal tissues, such as placental tissue
and umbilical cord blood, do not require these painful inva-
sive procedures, and can be donated with consent, but the
opportunity to donate these cells does not occur regularly.
Also, early clamping and draining of the umbilical cord blood
has been found to significantly lower hemoglobin levels in
new borns,5 and also affects the child’s neurodevelopment.6
Subsequently the World Health Organization (WHO) rec-
ognizes the dangers of early cord clamping and recommend
the cord should not be clamped ‘‘earlier than necessary’’.7
With our ever-growing, ever-aging population, the hunt for
potential treatment of many more diseases and conditions
continues, and the need for a safe, cheap, abundant source of
stem cells grows.
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Menstrual blood-derived mesenchymal stem cells
From menarche to menopause, healthy women undergo a
continuous reproductive cycle in constant preparation for
conception and childbirth. Single eggs are matured and re-
leased, and the uterus prepares for possible conception. If this
does not happen, the woman menstruates, and the cycle starts
again. Remarkably, this cyclical deterioration, shedding, and
regeneration of the uterine lining occurs without the forma-
tion of any scarring: each cycle bringing new, perfectly
functioning uterine tissue, suggesting stem cell-like activity.
This level of controlled tissue remodeling is not found in any
other organ in the body,8 and in 2004 stromal stem cells were
first harvested through a hysterectomy.9
Even though 37,000 women undergo a hysterectomy each
year on the NHS,10 this invasive, nonreversible procedure has
the same disadvantages to the other adult stem cell sources.
Also, being required by women with conditions affecting the
reproductive system means a transplantation could be detri-
mental for the recipient.
As the menstrual cycle involves the building and shedding
of the endometrium, in 2007 it was correctly postulated that
menstruated blood contains mesenchymal stromal cells.11
Menstrual blood-derived mesenchymal stem cells (MenSC)
are not limited in the way embryonic and other adult stem
cells are: menstrual blood is a waste blood, shed from every
healthy woman of reproductive age. It can be painlessly col-
lected with every menstrual cycle, holding the potential for cell
therapy that meets the growing demand on health care.
Researchers are beginning to understand the potential fu-
ture applications of these cells. In animal models, MenSC
have been used in the treatment of lung injury,12 spinal cord
injury,13 soft tissue damage,14 and critical limb ischemia,15 as
well as improve cardiac function,16–18 and treatment of heart
failure.19,20 Peripheral nervous system disorders have been
treated,21 the outcomes of impairments after ischemic stroke
have been improved with a transplantation of MenSC,22 and
Alzheimer’s disease-like symptoms have also been bet-
tered.23 Premature ovarian failure,24 ovary injury as a result
of cancer treatment,25 and a range of cancer types have been
treated with MenSC,26–29 including allogeneic MenSC
treatment in mice.30 Further success has been found in the
treatment of liver failure,31,32 liver injury,33 including that
from liver fibrosis,34 and liver function has been improved
after sepsis.35 Finally, hyperglycemia was improved in mice
with type 1 diabetes.36 In human models, with further clinical
trials underway for patients with type 1 diabetes, lung damage,
and liver cirrhosis, women with Asherman’s syndrome re-
ceived successful treatment from autologous MenSC trans-
plants,37 and four patients with multiple sclerosis received
allogeneic transplantations in four separate injections with
no adverse effects and no disease progression after a 1-year
follow-up,38 suggesting that future treatment could be sourced
from allogeneic MenSC transplants.
With these experiments showing MenSC having the po-
tential to treat a range of diseases and conditions, being de-
scribed as potential ‘‘off-the-shelf’’ treatments for a range of
ailments,3,20,36 it can certainly be argued that MenSC will be
part of the future of medicine. There is an ever-growing un-
derstanding of the clinical outputs of MenSC, particularly in
comparison to other sources of stem cells, such as bone
marrow,31,39–44 or isolation,2,44,45 culture,18,46,47 and differ-
entiation protocols.14,48 However, minimal work has been
done to understand the attitude women (and men) have to-
ward this therapy. Without the support of the public, and
women willing to donate menstrual blood samples, there is
little sense in continuing research. By speaking to the public,
it will be understood whether there would be a positive re-
ception of the potential therapy, and particularly whether the
source of the cells will be morally accepted by patients. The
collection method should also be discussed, as this will directly
influence a woman’s willingness to donate menstrual blood;
without willing donors and an acceptable donation protocol,
there will be insufficient quantities of MenSC for use in re-
search and eventually therapy. With a positive reception from
the public, pressure would be put on the science and medical
communities to further the research in this field. These attitudes
and understanding of the human factors related to the donation
of menstrual blood, including the potential barriers of men-
strual blood collection, were collected using a questionnaire.
Even though samples from younger donors have faster
proliferation rates,49,50 MenSC have still been successfully
derived and used in and ex vivo from women up to 45 years of
age.48,51,52 Being such a cheap, easily accessible, and readily
available source of cells for therapy, it must be argued that it
is still worth collecting samples of menstrual blood from all
premenopausal women when they can still be used for clin-
ical application. Therefore, it is still important to include
women from a broad age range in the survey.
Materials and Methods
Participants and recruitment
Women over the age of 18 were recruited from local uni-
versities, offices, and leisure centers to fill in a questionnaire
after reading an introduction to the topic with a description
of general terms. These locations were chosen to recruit par-
ticipants from as broad a demographic as possible. All par-
ticipants were asked to provide informed consent and were
provided the opportunity to ask questions. A total number of
170 questionnaires were handed out, with 102 being returned.
Two questionnaires were excluded from the study for failing to
follow the questionnaire format. No incentive was provided for
questionnaire completion. This research was approved by the
Nottingham Trent University Ethics Clearance Subcommittee.
Survey
The questionnaire consisted of 20 questions with extra
space for additional comments. Questions stemmed from five
key themes: age and medical history, menstruation percep-
tion and experience, knowledge of MenSC, donation of
MenSC, and receiving MenSC therapy. The brief medical
history included questions such as whether the participant had
given birth or donated peripheral blood in the past, and whether
she menstruated. In addition to general demographic questions
we also gathered information on childbirth and blood donation
history. The reason for doing this is to consider the hypotheses
that women with history of childbirth and therefore having
been in contact with a series of bodily fluids are more com-
fortable donating menstrual blood. Similarly, women already
happy to donate peripheral blood are happy to donate a similar,
waste blood. Women who did not menstruate were not asked if
they would donate their menstrual blood and the corresponding
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questions, and they were directed straight to the last section of
the questionnaire.
Data analysis
Data analysis was undertaken for quantitative components.
Descriptive statistics were utilized where appropriate. Pear-
son chi-squared tests, and paired t-tests were used. p-Values
<0.05 were considered significant. Open-ended, free text
questions supplemented quantitative data, adding context to
participants’ quantitative responses.
Results
Age and medical history
A total of 100 participants completed questionnaires. Only
adult women were considered (18+ years). Asking the par-
ticipants for a brief medical history, 36% of participants had
given birth before, 34% had donated blood before, and none
of the participants had donated stem cells in the past, in-
cluding donating umbilical cord blood after giving birth.
Nine percent were on contraception that stops a monthly
bleed, and 18% of participants did not menstruate due to
being menopausal or for other health reasons, such as being
severely underweight.
There was no significant relationship between age and
willingness of menstruating women to donate, as shown by a
Pearson chi-squared test (X(4) = 7.207, p = 0.125) (Table 1).
However, in women 25–32 years of age and 33–40 years of
age, 84% and 89%, respectively, were willing to donate their
menstrual blood, showing that women of these ages are
perhaps most open to the concept. There was also no sig-
nificant relationship between women having given blood
before and being willing to donate, as found with a Pearson
chi-squared test (X(1) = 0.054, p = 0.816), 76% of women
who had given blood would donate menstrual blood, com-
pared with 79% of women who had not. The same was
found of women who had previously given birth with their
willingness to donate (X(1) = 0.414, p = 0.520), 83% of
women who had given birth would donate menstrual blood,
whereas 76% of women who had not given birth would
donate.
Menstruation perception and experience
Regarding the menstruating participants’ perception of their
periods, they were asked to rate their experiences of men-
struation on a scale 1 to 10, from very negative to very positive,
respectively. A Pearson chi-squared test showed there was
no significant association between a woman’s period rating
and willingness to donate (X(8) = 4.582, p = 0.801). The mean
(standard error) period experience score was 4.5 (–0.4), with
Table 1. Participants’ Willingness to Donate
Menstrual Blood Depending on Age Group,
Previous Blood Donation, and Motherhood
Study
Percentage of
participants
surveyed
Percentage
that would
donate
menstrual
blood p
Age group 0.125
18–24 years 18 64
25–32 years 28 84
33–40 years 21 89
41–48 years 16 70
49–55 years 9 n/aa
56+ years 8 n/aa
Previous blood
donationb
0.816
Has previously
donated blood
34 76
Has not
previously
donated
66 79
Motherhood 0.520
Has given birth 36 83
Has not given
birth
64 76
aFigures not available as participants are no longer able to donate.
bBlood donations other than menstrual blood.
FIG. 1. Effect of knowledge of
MenSC donation on participants’
period experience rating. MenSC,
mesenchymal stem cells.
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26% of menstruating women rating their opinion on their pe-
riod as positive (a score of >5), and the remaining 74% rating
it as negative or neutral (a score of £5). The same question
was asked again, but on the pretence that the participants
were able to donate MenSC. The period rating increased in
40% of cases and decreased in 5%, with 55% of participants’
period rating remaining unchanged (Fig. 1). A paired t-test
shows a significant increase in participants’ rating of their
period (t(69) = -4.524, p = 0.001) after being made aware about
MenSC donation (mean score = 5.6 – 0.4).
Participants were also asked about their preferred menstrual
hygiene products, because menstrual blood samples would be
collected in a menstrual cup-style device, which is worn in-
ternally in the vaginal canal similarly to a tampon (Fig. 2).
When relating a menstruating woman’s preferred men-
strual hygiene products with their willingness to donate
menstrual blood, a Pearson chi-squared test showed there was
no significant association between the hygiene product
groups (X(6) = 2.919, p = 0.819), with the percentage of men-
struating women willing to donate ranging between 69% and
100% (Table 2). There was also no significant relation-
ship between willingness to donate menstrual blood with pre-
ferred menstrual hygiene products worn internally, such as
tampons or menstrual cups (X(1) = 0.012, p = 0.914). Overall,
78% of women who have used an internal menstrual hygiene
product were willing to donate menstrual blood, compared
with 77% of women who have not.
Knowledge of MenSC
Menstruating participants were asked if they had heard of
MenSC before, with 16% answering affirmatively, and of
them 73% rated their opinion on MenSC as positive (a score
of ‡6, where 1 is very negative and 10 is very positive). The
mode score was 10, median 8, and only 3% of participants
gave a score below 5 (Fig. 3).
To add context to these scores, open-ended questions of
participant thoughts on MenSC discloses themes, including
menstrual blood being waste blood, so it being good to put to
use, a want to develop treatment, but conversely and nega-
tively that the idea could be ‘‘gross,’’ or ‘‘messy’’ (Table 3).
Donation of MenSC
The majority of women were generally willing to donate
MenSC; 78% of menstruating participants would donate a
FIG. 2. Menstrual cup and
its use.
Table 2. Participants’ Willingness to Donate Menstrual Blood Depending on Preferred Menstrual
Hygiene Product (Internal and External)
Study
Percentage of
participants surveyed
Percentage that
would donate menstrual blood p
Preferred menstrual hygiene product 0.819
Sanitary towel 36 77
Tampon 30 75
Menstrual cup 3 100
Combinationa: Tampons and sanitary towels 22 69
Combination: Menstrual cups and sanitary towels 5 100
Combination: Tampons and menstrual cups 4 100
Type of menstrual hygiene product used: 0.914
Internal (i.e., tampon, menstrual cup) 64 78
External (i.e., sanitary towel) 36 77
aParticipants that regularly use more than one type of menstrual hygiene product.
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FIG. 3. Opinion of MenSC
donation, for participants who
have knowledge of it.
Table 3. Attitudes Toward Mesenchymal Stem Cells and Menstrual Blood Donation
Initial question and answer Follow-up question Participant response examples
Had you heard before
today that menstrual
blood contains stem
cells?
Yes What thoughts come to
mind when you think
that menstrual blood
could be used in cell
therapy?
‘‘Menstruation affects almost 50% of the population,
making it a very accessible means of cell research’’
‘‘I love it. Fantastic to think the blood I have can be used to
save people’s lives’’
No ‘‘How? What happens to the blood between collection +
administration as cell therapy? Also, ew/gross/messy!’’
‘‘Seems like an excellent use of a waste product but some
people might feel icky about it’’
Would you donate your
menstrual blood?
Yes Explain your answer ‘‘I don’t see why you wouldn’t when it’s just a waste
product from your body it might as well be put to good
use’’
‘‘If I felt I could help in any way to improve the lives of
others in such a simple way it can only be a good thing’’
‘‘It seems a very easy donation to make for an important
reason’’
No ‘‘Because I would feel disgusted maybe hygiene reasons
giving where it comes from, i.e., your vagina’’
‘‘wouldn’t feel confident and necessary’’
‘‘theoretically I would, but practically I probably wouldn’t
for health reasons, I can’t donate blood, would the same
apply here?’’
Would you use a menstrual
cup, or try using one for
the first time, to donate
your menstrual blood?
Yes Explain your answer ‘‘I have never used a cup before but I would be willing to
give it a go to help someone with stem cells that would
help someone else’’
‘‘I currently use a menstrual cup, I found it empowering’’
‘‘I’ve heard people comment positively on this method
generally. Why not kill two birds with one stone?’’
No ‘‘have tried cups, but didn’t get on with them, tried for
environmental reasons’’
‘‘I want my periods to be as unobtrusive as possible, with
minimal fuss or potential for embarrassment. I imagine
using a cup is less comfortable, more hassle + less
convenient’’
‘‘menstrual cups are not very hygienic more likely to get
toxic shock syndrome’’
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sample of menstrual blood for cell therapy. When asked to
explain their answer, of the woman willing to donate, key
themes included wanting to help people and the development
of medicine, menstrual blood being easy to donate, and using
a waste substance. Of participants not willing to donate, fears
of health affecting whether donation is possible and requiring
more information prevented willingness to donate. Con-
fidence and feelings of the donation being unhygienic were
also reasons for not donating MenSC (Table 3). A Pearson
chi-squared test showed a significant relationship between
women willing to donate menstrual blood and those willing
to use a menstrual cup to do so (X(1) = 40.846, p = 0.001).
Overall, 92% of women who would donate menstrual blood
would use a cup, and while this is perhaps unsurprising for
those who already do so regularly, it is worth noting that 73%
would use a cup for the first time to donate. Reasons given for
this include having already heard positive things about
menstrual cups, and the fact it would be for a beneficial
purpose (Table 3). For those that would not be willing to use a
menstrual cup to donate, women were adverse due to having
already tried it and not got on with it, having the pre-existing
thoughts that they would be uncomfortable, and the cups not
being very hygienic (Table 3).
Receiving MenSC therapy
All women, whether they menstruated or not, were asked if
they would accept cell therapy from MenSC. While 7% of
participants did not answer the question, 91% of menstruat-
ing participants said they would receive MenSC. Open-ended
responses explaining participants’ answers include that the
source of treatment did not matter, and if help was needed,
then any treatment would be welcome (Table 4). As the de-
pendant and independent variables were categorical, a Pearson
chi-squared test was used. As expected, the test showed a
significant relationship between women who would donate
MenSC for therapy and those accepting therapy (X(1) = 7.883,
p = 0.005), with 98% of women willing to donate MenSC also
willing to accept MenSC therapy. Of the women who would
not donate their MenSC, 77% would still accept MenSC cell
therapy. This would often be due to women having a chronic
illness, as women felt they were unfit for donation for health
Table 4. Receiving Mesenchymal Stem Cells Therapy
Initial question and answer
Follow-up
question Participant response examples
Would you accept therapy
from a menstrual blood
sample if you needed the
treatment?
Yes Explain your
answer
‘‘I don’t see why using menstrual blood is any different from
other blood- it all comes from our bodies!’’
‘‘I have chronic kidney disease + high blood pressure, so if it
would save my life, then yes’’
‘‘I imagine I would be willing to try anything’’
No ‘‘Undecided would rather not have a blood transfusion’’
‘‘Would like to know a bit more on how you donate before
actually donating, depends if being on the pill affects it,
depends if I’m having a bad period. if it’s proven to work
& be hygienic then yes [would donate]’’
‘‘Does not feel right. Would have to think about it in more
detail’’
Table 5. Further Comments
Further comments
theme Participant response examples
Contraception ‘‘I don’t currently have periods (contraception) but would be happy to use a menstrual cup to donate
when I do’’
‘‘If I was to menstruate every month and it could be donated, I would do this’’
Blood donation ‘‘The only reason I haven’t donated blood or anything before is because I am scared of the pain & the
process but I don’t feel that this would be a problem with menstrual blood donation’’
‘‘And it’s all good for people with a fear of needles’’
Health ‘‘My contraception is an IUD for treatment of endometriosis. I did not choose to not menstruate, it is a
side effect of my treatment. If I could be involved in something like this I would, but would have
doubts about whether my hormone imbalance or treatment would affect it.’’
‘‘Would the blood be ok if I’m on levothyroxine?’’
Taboo ‘‘By donating menstrual blood, women may become more open in discussing their periods, something
which I think is really important, rather than it being viewed as a dirty process or something to be
embarrassed by’’
‘‘If menstrual blood was seen as something useful it may dispel some of the taboos around it + make
young women more comfortable with the whole idea’’
IUD, intrauterine device.
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reasons but would appreciate treatment. Others would feel
uncomfortable donating but would still accept MenSC treat-
ment if they were ill (Table 4). Of the women that would not
accept MenSC therapy, women stated the treatment would
make them feel uncomfortable, or they choose to not accept
blood transfusions for personal reasons.
Further comments revealed several women wanted to re-
iterate their ill health and the wish to donate or receive
MenSC if they were able to do it. Women who were currently
on contraception that prevented menstruation stated they
would donate when they stopped taking it. Donating MenSC
was more appealing than donating blood or other stem cells
as the donation does not require needles and would be rela-
tively painless. Finally, the menstrual taboo was mentioned,
the donation of MenSC being a potential dispelling agent of
the stigma surrounding menstruation (Table 5).
Limitations
With little prior research to the topic of menstrual blood
donation and attitudes toward MenSC therapy, there has been
little consideration of the barriers to acceptance. History of
childbirth, whole blood donation, and stem cell donation
were used as key variables among age and menstruation to
minimize the number of demographic questions on the
questionnaire. This was to increase the number of returned
questionnaires. There is an unlimited number of potential
socioeconomic, cultural, and medical factors that could affect
women’s attitudes and willingness to donate menstrual blood
or MenSC therapy. Therefore, future work can overcome this
limitation by exploring other factors.
Revolving around this taboo subject, another limitation of
this questionnaire is that data would be taken from women
willing to do the survey, which may be women less affected
by the menstrual taboo.
Physical questionnaires were distributed from one geo-
graphical region. Where participant comfort and wellbeing is
paramount, physical questionnaires were less intrusive for
the participants and women could choose how much they
engaged with the researcher, including asking questions.
Where this could limit the range of demographics within the
sample, there is no reason to believe the sample is nonrep-
resentative of the population.
Discussion
MenSC undoubtedly is part of the future of cell thera-
py,3,14,25,47,53 becoming more attractive than other stem cell
banks, such as umbilical cord blood.54 With this in mind, it is
important that donor acceptance and barriers to uptake be
fully considered. Without the acceptance and support from
women, there would be no future for MenSC therapy.
As a subject, MenSC therapy and the existence of MenSC
does not have a huge public awareness: 16% of women sur-
veyed were aware of MenSC.
With a questionnaire return rate of 60%, this shows that
many women are prepared to talk about menstruation, cell
therapy, and other sensitive topics. With popular culture
beginning to show realistic depictions of menstrual blood,
including TV adverts55 and film,56 and parity in medicine
improving with the increase in awareness and improvement
of treatment for conditions such as endometriosis,57 and
urinary incontinence and pelvic organ prolapse,58 it is pos-
sible that the menstrual taboo is beginning to dissipate.
However, some women may have avoided participating in
the survey due to this menstrual taboo.
This study highlights the overwhelmingly positive attitude
the female public has to the donation of MenSC as well as
using a menstrual cup to donate the menstrual blood sample,
and expressing a positive response to receiving cell therapy
from MenSC. Encouragingly, it appears that women of all
ages are willing to donate menstrual blood, with no difference
being made as to whether they had given birth. This means
efforts to encourage women to donate their menstrual blood
for MenSC therapy will not have to be directed to a particular
demographic of women, and a large pool of women will be
available for recruitment in preparation for MenSC therapy to
become a reality. All ages of women, mothers and non-
mothers, women with and without previous donation expe-
rience, can be supported and support each other in their
MenSC donation.
Although not statistically significant, it could be argued that
younger women are slightly less inclined to donate MenSC
compared with women 25–40 years of age. This could be due
to less knowledge on stem cell therapy, and being generally
fitter and healthier: health care not being on their minds.
Educating the younger audience could be all it takes to maxi-
mize the number of women willing to donate MenSC. Data
tailed off for women 41 years of age onward because biolog-
ically they were less likely to still be menstruating.
Although whether or not a woman had donated blood
previously had no significant impact on her willingness to do-
nate MenSC, several women had a fear of needles, preventing
them from donating blood. Therefore, donating MenSC would
be more appealing to these women, so the lack of needles
could be a persuading factor utilized when recruiting potential
donors.
There is no significant relationship between how a woman
chooses to deal with her period (her preferred menstrual
hygiene products), and her willingness to donate menstrual
blood. This is a useful finding, as adverts and campaigns do
not need to be targeted to women who, for example, are
extremely ecoconscious and only ever use reusable menstrual
hygiene products. Saying this, women who already have
experience using a menstrual cup are already happy to donate
menstrual blood in this way. For these women, donating
MenSC would require minimal change to their monthly rou-
tine; they would not need to learn how to use a new product,
which can take a multiple cycles’ practice, and would be
available to donate virtually immediately. However, with
such a large percentage of women so willing to donate their
menstrual blood they would be prepared to use an entirely
new menstrual hygiene product, there is extremely promising
future for the donation of menstrual blood with a menstrual
cup. With the knowledge that many women could be sud-
denly learning how to use a new product, it is important to
understand how best to support this choice. A small prelim-
inary study showed that for women learning to use a men-
strual cup for the first time, the more support and guidance
she received, the better her experience, and faster the learning
curve.59 Therefore, for women who have never used a men-
strual cup before, a more positive experience and conse-
quently possibly higher returning rate can be achieved by
being given a menstrual cup and supported through first use.
As several women surveyed also had incorrect preexisting
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ideas surrounding menstrual cups, education on the subject,
their safety, comfort, and ease of use must be highlighted for
future donors.
No participants had previously donated stem cells, sourced
from bone marrow, umbilical cord blood, or any other source.
Therefore, no conclusion could be drawn from a woman’s
likeliness to donate had she previously donated stem cells.
Finally, no significant association was found between
women’s perception of menstruation, and their willingness to
donate: women who thought their periods were ‘‘terrible’’ as
well as women who rated their period maximally were sim-
ilarly willing to donate their MenSC. Therefore, with the aim
of recruiting donors of MenSC, there is no need to find
women, for example, who find their periods a joyous occa-
sion, or those who never have period cramps. Interestingly, it
was found that women’s rating of their period improved in
40% of respondents after being able to donate MenSC: par-
ticipant comments suggest it was the idea of helping someone
in need, or using a waste blood that would otherwise be
thrown away that increased this experience rating, and the
feelings of shame associated with menstruation being re-
duced. If donating MenSC can be a benefit for society as well
as help individual women feel more positive about a natural
bodily process, then the donation of MenSC is something
to be celebrated. This must be highlighted to women when
recruiting donors.
Implications
The results of this study show there is no need to urge
women of specific demographics, including age, childbirth,
and blood donation to donate menstrual blood, as these fac-
tors have no significant impact on women’s willingness to
donate. Other factors such as an increase in education, pos-
sibly in schools, could mean that more women are aware of
donation and sample collection safety and hygiene. Support
given to donating women could also lead to a positive do-
nation experience and an improvement in their perception of
menstruation, overcoming the menstrual taboo. Further in-
vestigation is needed regarding attitudes toward MenSC and
donation requirements, to reveal potential barriers to MenSC
donation and investigate how menstrual blood could be do-
nated. Collection devices and donation systems can then be
optimized for MenSC therapy needs and introduced into
current health care systems.
Conclusions
As the first study of human factors surrounding MenSC
and the donation of menstrual blood, there is a generally
positive perception of MenSC, with 78% of menstruating
women willing to donate and 91% of all women willing to
accept MenSC therapy. This support of MenSC is highly
positive, as the support from the public and individual future
donors of menstrual blood suggests there is potential for
MenSC therapy from a human factors’ angle. Age, history of
childbirth and donating blood, perception of menstruation,
and preferred menstrual hygiene product have no significant
relationship with a woman’s willingness to donate, meaning
that all women can be encouraged to donate. The exact do-
nation method should also now be analyzed in terms of
women’s acceptance and clinical suitability.
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